Percheron Therapeutics Limited has released a press release.
Appendix 4C - quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Response to ASX Price Query
- Positive preliminary results from ATL1102 DMD Phase II trial
- ATL1102 for DMD European regulatory interactions
- Acromegaly Early Access Program Status Update
- Phase II DMD clinical trial on track for dosing completion
Later from Percheron Therapeutics
- Dosing completed in ATL1102 Phase II DMD trial
- AGM Presentation 2019
- Suspension from Official Quotation
- Positive results reaffirm plans to advance ATL1102 to P2b
- Antisense Therapeutics Limited - Listed Options raise $5.5M
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics